Publication Name	World Journal of Hepatology
Manuscript ID	90421
Country	Brazil

Received	2023-12-03 16:29
Peer-Review Started	2023-12-03 16:30
To Make the First Decision
Return for Revision	2023-12-15 12:32
Revised	2024-01-04 21:52
Second Decision	2024-01-23 02:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-01-23 07:23
Articles in Press	2024-01-23 07:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-02-19 07:00
Publish the Manuscript Online	2024-02-27 11:58

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Advancements in autoimmune hepatitis management: Perspectives for future guidelines
Manuscript Source	Invited Manuscript
All Author List	Marcos Mucenic
ORCID	Author(s) ORCID Number Marcos Mucenic http://orcid.org/0000-0001-9389-2236
Funding Agency and Grant Number
Corresponding Author	Marcos Mucenic, MD, PhD, Doctor, Doctor, Medical Assistant, Liver Transplantation Group, Santa Casa de Porto Alegre, Independencia 75, Porto Alegre 90035-070, RS, Brazil. mmucenic@gmail.com
Key Words	Autoimmune Hepatitis; Treatment; Immunosuppression; Relapse; Remission induction
Core Tip	Autoimmune hepatitis guidelines consider corticosteroids as first-line treatment, including budesonide as an option in patients without cirrhosis. Azathioprine is recommended to reduce corticosteroid doses and side effects. Nevertheless, there are concerns regarding its long-term malignancy risks. Recent publications suggest that these guidelines may be outdated. The efficacy of budesonide can be limited to patients with lower aminotransferases levels. The potential superiority of mycophenolate mofetil to azathioprine is under scrutiny. Additionally, there are controversies regarding treatment suspension, with a potential role for chloroquine for long-term maintenance treatment. Other therapeutic agents are still in the initial stages of research.
Publish Date	2024-02-27 11:58
Citation	Mucenic M. Advancements in autoimmune hepatitis management: Perspectives for future guidelines. World J Hepatol 2024; 16(2): 135-139
URL	https://www.wjgnet.com/1948-5182/full/v16/i2/135.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i2.135

Full Article (PDF)	WJH-16-135-with-cover.pdf
Full Article (Word)	WJH-16-135.docx
Manuscript File	90421_Auto_Edited-LJH-YJP.docx
Answering Reviewers	90421-Answering reviewers.pdf
Audio Core Tip	90421-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	90421-Conflict-of-interest statement.pdf
Copyright License Agreement	90421-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90421-Language certificate.pdf
Peer-review Report	90421-Peer-review(s).pdf
Scientific Misconduct Check	90421-Bing-Liu JH-2.png
Scientific Misconduct Check	90421-CrossCheck.png
Scientific Editor Work List	90421-Scientific editor work list.pdf
CrossCheck Report	90421-CrossCheck report.pdf